Social Activist Demands Lab Testing Of Ayurvedic Medicine Used For Joint Pains

Jammu: (UNI) A Jammu based social activist Sukesh C Khajuria has sought laboratory testing of Ayurvedic medicine, being used for treating the joint pains.

The social activist had expressed his apprehensions related to the Ayurvedic composition known as ‘Batnashak Batika”, which he claimed is increasingly being utilized for the treatment of joint pains, particularly in patients who have suffered from ‘Chikungunya’ in Jammu and Kashmir. He wrote to the drug authorities in J&K that ‘Batnashak Batika’ reportedly demonstrates swift efficacy in alleviating post-Chikungunya joint pains, contrary to the conventional understanding that Ayurvedic herbal medicines typically facilitate gradual healing and recovery.

Given the remarkable and expeditious healing attributed to this Ayurvedic medicine, I harbour reservations regarding its composition,” he added.

He requested the Drug controller Jammu and Kashmir to conduct a thorough chemical examination of the composition to determine whether any steroids or potentially harmful substances have been incorporated to expedite relief, posing potential health risks to consumers. Khajuria and urged the authorities for a comprehensive chemical examination of the Ayurvedic medicine at the drug laboratory and disseminate the findings to the general public for the collective benefit of society.

He said he had alerted the drug authorities of Jammu and Kashmir, Union Health Minister and other central and union territory officials about the dangers of sale of such drugs.

Related Posts

  • Pharma
  • June 25, 2025
  • 79 views
Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

A major face-off is expected in India’s growing anti-obesity treatment market, as Danish pharma giant Novo Nordisk rolled out its blockbuster weight-loss drug Wegovy on Tuesday, just a month after…

  • Pharma
  • June 25, 2025
  • 104 views
Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

Hyderabad:  Aurobindo Pharma Ltd wholly owned step-down subsidiary CuraTeQ Biologics has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India